Risk factors associated with pulmonary arterial hypertension in patients with systemic sclerosis and implications for screening

European Respiratory Review

Volumn 20, Issue 122, 2011, Pages 270-276

  Denton, C P ^a   Hachulla, E ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIV LILLE   (France)

Author keywords

Pulmonary arterial hypertension; Screening; Systemic sclerosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AUTOANTIBODY; BOSENTAN; CARBON MONOXIDE; PLACEBO;

DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; HEART CATHETERIZATION; HUMAN; INTERMETHOD COMPARISON; LUNG DIFFUSION CAPACITY; LUNG FUNCTION TEST; MORBIDITY; NON INVASIVE PROCEDURE; PREDICTIVE VALUE; PROGNOSIS; PULMONARY HYPERTENSION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; SYSTEMIC SCLEROSIS;

DISEASE PROGRESSION; ECHOCARDIOGRAPHY; HUMANS; HYPERTENSION, PULMONARY; MASS SCREENING; RESPIRATORY FUNCTION TESTS; RISK FACTORS; SCLERODERMA, SYSTEMIC; SURVIVAL RATE;

EID: 82555191287     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00006111     Document Type: Review

References (56)

1. Nihtyanova SI, Tang EC, Coghlan JG, et al. Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study. QJM 2010; 103: 109-115.
2. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007; 66: 940-944.
3. Mouthon L, Bérezné A, Bussone G, et al. Scleroderma renal crisis: a rare but severe complication of systemic sclerosis. Clin Rev Allergy Immunol 2011; 40: 84-91.
4. Steen VD, Medsger TA Jr. Long-term outcomes of scleroderma renal crisis. Ann Intern Med 2000; 133: 600-603.
5. Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69: 1809-1815.
6. Mukerjee D, St George D, Knight C, et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford) 2004; 43: 461-466.
7. Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005; 52: 3792-3800.
8. Avouac J, Airò P, Meune C, et al. Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. J Rheumatol 2010; 37: 2290-2298.
9. Humbert M, Yaici A, de Groote P, et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum 2011; [Epub ahead of print DOI:10.1002/art.30541].
10. Hachulla E, de Groote P, Gressin V, et al. The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. Arthritis Rheum 2009; 60: 1831-1839.
11. Cox SR, Walker JG, Coleman M, et al. Isolated pulmonary hypertension in scleroderma. Intern Med J 2005; 35: 28-33.
12. Hunzelmann N, Genth E, Krieg T, et al. The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology (Oxford) 2008; 47: 1185-1192.
13. Shand L, Lunt M, Nihtyanova S, et al. Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model. Arthritis Rheum 2007; 56: 2422-2431.
14. Hachulla E, Launay D, Mouthon L, et al. Is pulmonary arterial hypertension really a late complication of systemic sclerosis? Chest 2009; 136: 1211-1219.
15. Kawut SM, Taichman DB, Archer-Chicko CL, et al. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003; 123: 344-350.
16. Hachulla E, Carpentier P, Gressin V, et al. Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR-Scle ́rodermie study. Rheumatology (Oxford) 2009; 48: 304-308.
17. Condliffe R, Kiely DG, Peacock AJ, et al. Connective tissue diseaseassociated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009; 179: 151-157.
18. Hachulla E, Launay D, Yaici A, et al. Pulmonary arterial hypertension associated with systemic sclerosis in patients with functional class II dyspnoea: mild symptoms but severe outcome. Rheumatology (Oxford) 2010; 49: 940-944.
19. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40: 780-788.
20. Galiè N, Rubin LJ, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008; 371: 2093-2100.
21. Le Pavec J, Humbert M, Mouthon L, et al. Systemic sclerosisassociated pulmonary arterial hypertension. Am J Respir Crit Care Med 2010; 181: 1285-1293.
22. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023-1030.
23. Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010; 137: 376-387.
24. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009; 119: 2250-2294.
25. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-2537.
26. O'Callaghan DS, Dorfmuller P, Jaïs X, et al. Pulmonary venoocclusive disease: the bê;te noire of pulmonary hypertension in connective tissue diseases? Presse Med 2011; 40: e65-e78.
27. Chang B, Schachna L, White B, et al. Natural history of mildmoderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma. J Rheumatol 2006; 33: 269-274.
28. Schachna L, Wigley FM, Chang B, et al. Age and risk of pulmonary arterial hypertension in scleroderma. Chest 2003; 124: 2098-2104.
29. Plastiras SC, Karadimitrakis SP, Kampolis C, et al. Determinants of pulmonary arterial hypertension in scleroderma. Semin Arthritis Rheum 2007; 36: 392-396.
30. Scorza R, Caronni M, Bazzi S, et al. Post-menopause is the main risk factor for developing isolated pulmonary hypertension in systemic sclerosis. Ann N Y Acad Sci 2002; 966: 238-246.
31. Beretta L, Caronni M, Origgi L, et al. Hormone replacement therapy may prevent the development of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Scand J Rheumatol 2006; 35: 468-471.
32. Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003; 48: 516-522.
33. Coral-Alvarado P, Rojas-Villarraga A, Latorre MC, et al. Risk factors associated with pulmonary arterial hypertension in Colombian patients with systemic sclerosis: review of the literature. J Rheumatol 2008; 35: 244-250.
34. Chandra S, Shah SJ, Thenappan T, et al. Carbon monoxide diffusing capacity and mortality in pulmonary arterial hypertension. J Heart Lung Transplant 2010; 29: 181-187.
35. Allanore Y, Borderie D, Avouac J, et al. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum 2008; 58: 284-291.
36. Nagaya N, Nishikimi T, Okano Y, et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 1998; 31: 202-208.
37. Williams MH, Handler CE, Akram R, et al. Role of N-terminal brain natriuretic peptide (NT-proBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J 2006; 27: 1485-1494.
38. Hesselstrand R, Wildt M, Ekmehag B, et al. Survival in patients with pulmonary arterial hypertension associated with systemic sclerosis from a Swedish single centre: prognosis still poor and prediction difficult. Scand J Rheumatol 2011; 40: 127-132.
39. Mathai SC, Bueso M, Hummers LK, et al. Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension. Eur Respir J 2010; 35: 95-104.
40. Simeoni S, Lippi G, Puccetti A, et al. N-terminal pro-BNP in sclerodermic patients on bosentan therapy for PAH. Rheumatol Int 2008; 28: 657-660.
41. Vachiéry JL, Coghlan G. Screening for pulmonary arterial hypertension in systemic sclerosis. Eur Respir Rev 2009; 18: 162-169.
42. Vonk MC, Sander MH, van den Hoogen FH, et al. Right ventricle Tei-index: a tool to increase the accuracy of non-invasive detection of pulmonary arterial hypertension in connective tissue diseases. Eur J Echocardiogr 2007; 8: 317-321.
43. Serra W, Chetta A, Santilli D, et al. Echocardiography may help detect pulmonary vasculopathy in the early stages of pulmonary artery hypertension associated with systemic sclerosis. Cardiovasc Ultrasound 2010; 8: 25.
44. Schreiber BE, Valerio CJ, Keir GJ, et al. Improving the detection of pulmonary hypertension in systemic sclerosis using pulmonary function. Arthritis Rheum 2011; [Epub ahead of print DOI: 10.1002/ art.30535].
45. Meune C, Avouac J, Airò P, et al. Prediction of pulmonary hypertension related to systemic sclerosis by an index based on simple clinical observations. Arthritis Rheum 2011; 63: 2790-2796.
46. Arunthari V, Burger CD, Lee AS. Correlation of pulmonary function variables with hemodynamic measurements in patients with pulmonary arterial hypertension. Clin Respir J 2011; 5: 35-43.
47. Delcour KS, Singla A, Jarbou M, et al. Does reduced lung diffusing capacity for carbon monoxide predict the presence of pulmonary hypertension? Am J Med Sci 2010; 340: 54-59.
48. Cavagna L, Caporali R, Klersy C, et al. Comparison of brain natriuretic peptide (BNP) and NT-proBNP in screening for pulmonary arterial hypertension in patients with systemic sclerosis. J Rheumatol 2010; 37: 2064-2070.
49. Chung L, Liu J, Parsons L, et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 2010; 138: 1383-1394.
50. Hesselstrand R, Scheja A, Shen GQ, et al. The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis. Rheumatology (Oxford) 2003; 42: 534-540.
51. Aggarwal R, Lucas M, Fertig N, et al. Anti-U3 RNP autoantibodies in systemic sclerosis. Arthritis Rheum 2009; 60: 1112-1118.
52. Mitri GM, Lucas M, Fertig N, et al. A comparison between anti-Th/To-and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement. Arthritis Rheum 2003; 48: 203-209.
53. Pendergrass SA, Hayes E, Farina G, et al. Limited systemic sclerosis patients with pulmonary arterial hypertension show biomarkers of inflammation and vascular injury. PLoS One 2010; 5: e12106.
54. Christmann RB, Hayes E, Pendergrass S, et al. Interferon and alternative activation of monocyte/macrophages in systemic sclerosis-associated pulmonary arterial hypertension. Arthritis Rheum 2011; 63: 1718-1728.
55. Khanna D, Saggar R, Furst DE, et al. Predictive value of noninvasive tests for the diagnosis of scleroderma-associated pulmonary hypertension: PHAROS registry. Arthritis Rhem 2010; 62: Suppl. 10, 729.
56. ClinicalTrials.gov. Early, simple and reliable detection of pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc) (DETECT). NCT00706082. http://clinicaltrials.gov/ct2/show/NCT00706082?term5NCT00706082&rank51 Date last updated: July 8, 2011. Date last accessed: July 11, 2011.